Skip to main content
International
Ask us anything:
  • About
        • About We challenge convention so healthy can be possible
        • Our Story
          • Amneal at-a-glance
          • Our Founders
          • Our Milestones
        • Our Purpose & Commitments
        • Our Culture
          • Rise, Lead, Succeed
        • Our Leadership
          • Executive Leadership
          • Board of Directors
        • Our Locations
        • Responsibility
          • The Amneal Patient Assistance Programs
          • Product Donations
          • National & Local Philanthropy
          • Compliance and Ethics
        • Patient Community Connections
          • Our Commitment to Parkinson's
        • Awards & Recognition
  • Products
        • Products We create essential medicines
        • Our Portfolio
          • Biosciences
          • Generic Products
          • Specialty Products
          • Product Catalog
        • Quality
        • Drug Safety
          • Adverse Event Reporting
          • Medical Inquiries
          • Product Complaints
        • Operations
  • Research & Development
        • Research & Development We invest significantly in new product development
        • Generics R&D
        • Specialty R&D
          • Drug Delivery Technologies
        • Product Partnering
  • Investors
        • Investors Become an Informed Investor
  • News
  • Careers
        • Careers Help make healthy possible
        • Total Rewards
        • Search Our Career Opportunities
  • Contact
  • Customer Login
Amneal Pharmaceuticals
  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds

Home Home  >  News  >  Press Releases

  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds
Normal
Press Release RSS Feed (opens in new window)
Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002
Dec 23, 2004
IMPAX Laboratories Announces Retirement of CFO
Dec 22, 2004
IMPAX Launches Generic Version of Wellbutrin SR 200mg Tablets
Dec 06, 2004
IMPAX Receives Final FDA Approval and First-to-File Status for Generic Version of Wellbutrin SR 200mg Tablets; Eleventh Approval in 2004
Nov 29, 2004
IMPAX to Present at First Albany Capital Growth Conference
Nov 16, 2004
IMPAX to Present at the Credit Suisse First Boston Healthcare Conference
Nov 09, 2004
IMPAX Reports Third Quarter 2004 Financial Results
Nov 05, 2004
IMPAX to Present at the 15th Annual CIBC Healthcare Conference
Nov 03, 2004
IMPAX Laboratories Postpones Third Quarter 2004 Financial Results Conference Call to Tuesday, November 9, 2004
Oct 27, 2004
Impax Laboratories to Hold Third Quarter 2004 Financial Results Conference Call Thursday, November 4, 2004
Oct 20, 2004
IMPAX to Present at C.E. Unterberg, Towbin Specialty Pharmaceutical Conference
Oct 01, 2004
IMPAX Announces Effectiveness of Registration Statement Relating to Resale of 1.250% Convertible Senior Subordinated Debentures Due 2024
Sep 24, 2004
IMPAX Receives Final FDA Approval for Oxycodone Hydrochloride Controlled Release Tablets, 80mg; Tenth Approval in 2004
Sep 15, 2004
IMPAX To Present at the Think Equity Partners' 2nd Annual Growth Conference
Sep 15, 2004
IMPAX to Present at the Banc of America Securities 34th Annual Investment Conference
Sep 08, 2004
IMPAX To Present at the 17th Annual Bear Stearns Health Conference
Sep 08, 2004
IMPAX and Teva Launch Omeprazole Delayed Release Capsules 20mg
Sep 01, 2004
IMPAX Comments on Lower Court Ruling Related to Generic Rilutek
Aug 04, 2004
IMPAX Announces Second Consecutive Profitable Quarter; Receives Three FDA Approvals in Second Quarter
Aug 02, 2004
IMPAX Receives Final FDA Approval for Metformin Hydrochloride Extended Release Tablets, 500mg; Ninth Approval in 2004
Jul 23, 2004
IMPAX Laboratories to Hold Second Quarter 2004 Financial Results Conference Call Wednesday, August 4, 2004
Jul 12, 2004
IMPAX Signs Distribution Agreements with Leiner Health Products, LLC for Loratadine Products
Jun 18, 2004
IMPAX Granted FDA 180-Day Exclusivity for Metformin HCl Extended Release Tablets, 500mg; Selectively Waived to TEVA Pharmaceuticals USA Inc.
Jun 15, 2004
IMPAX To Present at the Wachovia Securities 14th Annual Nantucket Equity Conference
Jun 14, 2004
IMPAX Files Registration Statement for Resale of Previously Issued 1.250% Convertible Senior Subordinated Debentures Due 2024
May 28, 2004
IMPAX Receives Final FDA Approval for Generic PROAMATINE; Eighth ANDA Approval in 2004
May 27, 2004
IMPAX Receives Final FDA Approval for Generic Version of Zyban; Seventh ANDA Approval in 2004
May 25, 2004
IMPAX to Present at the Friedman Billings Ramsey 8th Annual Growth Investor Conference
May 17, 2004
IMPAX Shareholders Re-Elect Board Members
May 17, 2004
IMPAX Receives Final FDA Approval for Generic Version of Sinemet CR; Sixth ANDA Approval in 2004
May 10, 2004
IMPAX Laboratories to Present at the Banc of America Health Care Conference
May 05, 2004
IMPAX Posts First Profitable Quarter Driven by Record Revenues; Received Five FDA Approvals in First Quarter
Apr 28, 2004
IMPAX Laboratories to Hold First Quarter 2004 Financial Results Conference Call Wednesday, May 5, 2004
Apr 19, 2004
IMPAX to Present at the CIBC Annual Biotechnology & Specialty Pharmaceuticals Conference
Mar 30, 2004
IMPAX Laboratories, Inc. Prices $82 Million of 1.250% Convertible Senior Subordinated Debentures
Mar 30, 2004
IMPAX Announces Proposed Private Placement of Convertible Senior Subordinated Debentures
Mar 23, 2004
IMPAX Receives Final FDA Approval for Generic Version of Declomycin; Fifth ANDA Approval in 2004
Mar 22, 2004
IMPAX Receives Final FDA Approval for Generic Version of Wellbutrin SR 150 MG
Mar 08, 2004
IMPAX Receives Tentative FDA Approval for Generic Version of Tricor Tablets; Fourth ANDA Approval of 2004
Mar 05, 2004
IMPAX Receives Final FDA Approval for Generic Version of Claritin-D 24-Hour; Third ANDA Approval of 2004 for IMPAX
Feb 27, 2004
IMPAX Receives Tentative FDA Approval for Generic Version of Allegra-D
Feb 27, 2004
IMPAX to Present at Lehman Brothers Healthcare Conference
Feb 19, 2004
IMPAX To Present at Smith Barney Specialty Pharmaceuticals Conference
Feb 17, 2004
IMPAX Reports Fourth Quarter and 2003 Financial Results; Received 9 FDA Approvals; Filed 8 Applications in Year
Feb 10, 2004
IMPAX Laboratories Postpones Fourth Quarter 2003 Financial Results Conference Call to Tuesday, February 17, 2004
Feb 03, 2004
IMPAX Laboratories to Hold Fourth Quarter 2003 Financial Results Conference Call Wednesday, February 11, 2004
Jan 29, 2004
IMPAX Announces Favorable Decision in Wellbutrin SR Patent Appeal
Jan 29, 2004
IMPAX to Present at Merrill Lynch Global Pharma, Device and Biotech Conference
Jan 28, 2004
IMPAX Receives FDA Approval for Generic Versions of Wellbutrin SR; Final Approval Issued for the 100 mg Strength
Jan 21, 2004
IMPAX To Present at Piper Jaffray Healthcare Conference
Jan 08, 2004
IMPAX to Present at J.P. Morgan Healthcare Conference
Jan 06, 2004
IMPAX Announces Organizational Changes

Investor Faq

Get answers to important investor relation questions.

More

Investor Tools

  • Email Alerts
  • RSS Feeds
  • Email Page

IR Contact

Get answers to your investor relation questions.

More
  • Privacy Policy
  • Copyright & Legal Disclaimer
  • Web Accessibility
© Amneal Pharmaceuticals LLC.
All rights reserved.
Powered By Q4 Inc. 5.86.0.1 (opens in new window)
Back to top